SCHEMBL24733588

SCHEMBL24733588

CC1CN(CC2CCOCC2)CC(C)C1(C)I

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GBA1 P04062 2/20 0.43
▸ SCN1A P35498 1/20 0.37
▸ SCN4A P35499 1/20 0.37
▸ SCN7A Q01118 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ SCN5A Q14524 1/20 0.37
▸ SCN9A Q15858 1/20 0.37
▸ SCN2A Q99250 1/20 0.37
▸ SCN3A Q9NY46 1/20 0.37
▸ SCN11A Q9UI33 1/20 0.37
▸ SCN8A Q9UQD0 1/20 0.37
▸ SCN10A Q9Y5Y9 1/20 0.37
▸ OPRM1 P35372 2/20 0.33
▸ CYP11B2 P19099 1/20 0.33
▸ CNR1 P21554 4/20 0.31
▸ CNR2 P34972 4/20 0.31
▸ CHRM2 P08172 2/20 0.31
▸ CHRM4 P08173 2/20 0.31
▸ ACHE P22303 1/20 0.31
▸ EBP Q15125 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24733575 0.87 SCN1A (0.42) GBA1SCN1ASCN4ASCN7AKCNH2
SCHEMBL23963905 0.77 GBA1 (0.50) GBA1SCN1ASCN4ASCN7AKCNH2
SCHEMBL21254312 0.74 EBP (0.41) GBA1SCN1ASCN4ASCN7AKCNH2
SCHEMBL30616172 0.73 GBA1 (0.46) GBA1SCN1ASCN4ASCN7AKCNH2
SCHEMBL8237680 0.73 GBA1 (0.46) GBA1SCN1ASCN4ASCN7AKCNH2
SCHEMBL23507432 0.71 GBA1 (0.42) GBA1SCN1ASCN4ASCN7AKCNH2
SCHEMBL18099389 0.70 GBA1 (0.50) GBA1SCN1ASCN4ASCN7AKCNH2
SCHEMBL18459033 0.69 GBA1 (0.42) GBA1KCNH2CYP11B2CHRM4ACHE
SCHEMBL22878336 0.69 GBA1 (0.46) GBA1SCN1ASCN4ASCN7AKCNH2
SCHEMBL17285960 0.69 GBA1 (0.46) GBA1SCN1ASCN4ASCN7AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022249006-A1 USE OF 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS NOVARTIS AG (CH) 2022-12-01 — — WO disclosed
Send feedback